Avion Wealth’s Galectin Therapeutics GALT Stock Holding History

Avion Wealth’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-237	Closed	–	–	1326
2025 Q1	$0	Buy	+237	New	+$332	﹤0.01%	1146

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avion Wealth's GALT Position: Q2 2025 in Review

Avion Wealth sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 237 shares.

Avion Wealth first reported a position in GALT in Q1 2025 and held it in 1 quarter. The position peaked at $0 in Q1 2025. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

Avion Wealth reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
Avion Wealth sold 237 Galectin Therapeutics shares in Q2 2025.
Avion Wealth first reported a position in Galectin Therapeutics in Q1 2025 and held it in 1 quarter.
Avion Wealth's Galectin Therapeutics position peaked at $0 in Q1 2025.
86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Avion Wealth's 13F filing for Q2 2025, filed 25 Jul 2025.